Semaglutide
GLP-1 receptor agonist for diabetes treatment and weight management
⭐⭐⭐⭐⭐Clinically Proven Results
Proven Weight Loss
Clinical programs with semaglutide show around 10–15% average body-weight reduction at therapeutic dosing.
Cardiometabolic Support
Improves glycemic control and cardiometabolic markers as part of a comprehensive plan.
FDA Approved*
Approved for type 2 diabetes and for chronic weight management at specific doses.
Contraindications & Precautions
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Known hypersensitivity to semaglutide
Use with Caution
- History of pancreatitis
- Gallbladder disease
- Diabetic retinopathy
- Severe gastrointestinal disease
- Renal impairment
- Pregnancy or breastfeeding
Results, Dosing & Side Effects
Weight-Management Outcomes
- Average weight loss ~10–15% with ongoing therapy
- Improvements in waist circumference and body composition
- Enhanced satiety and reduced caloric intake
- Better adherence with weekly dosing
Glycemic Benefits
- Meaningful reductions in HbA1c
- Low hypoglycemia risk when not used with insulin/sulfonylureas
- Supports cardiometabolic health
- Once-weekly injection for convenience
Clinical Trial Highlight
Dosing & Administration (Weight Management)
Route: Subcutaneous injection once weekly
Typical Titration:
- 0.25 mg once weekly × 4 weeks
- 0.5 mg once weekly × 4 weeks
- 1.0 mg once weekly × 4 weeks
- 1.7 mg once weekly × 4 weeks
- 2.4 mg once weekly (maintenance, as tolerated)
Injection Sites: Abdomen, thigh, or upper arm; rotate sites weekly.
Note: Diabetes dosing schedules may differ (e.g., 0.5–2.0 mg weekly based on indication and product).
Side Effects — Common (≥5%)
- Nausea, vomiting, diarrhea
- Constipation, abdominal pain
- Headache, fatigue
- Injection-site reactions
Side Effects — Serious (Rare)
- Pancreatitis
- Gallbladder disease
- Acute kidney injury (typically with dehydration)
- Severe hypoglycemia (when combined with insulin/sulfonylureas)
- Thyroid C-cell tumor risk observed in rodents (boxed warning)
Why Choose Semaglutide?
Semaglutide is a GLP-1 receptor agonist that targets key metabolic pathways—reducing appetite, improving glycemic control, and supporting sustainable weight loss with simple once-weekly dosing.
“I’ve lost 27 pounds in 16 weeks on semaglutide. Cravings are manageable, my energy is steady, and my blood sugar is finally on track.” — Jasmine K.
Mechanism of Action
- GLP-1 Receptor Activation: Increases glucose-dependent insulin secretion and lowers glucagon.
- Gastric Emptying: Slows gastric emptying to enhance satiety and reduce caloric intake.
- Central Appetite Effects: Acts on brain centers that regulate hunger and fullness.
- Metabolic Support: Improves glycemic control and supports cardiometabolic health.
*Approval details depend on indication, dose, and region. Educational content only—patients should consult a licensed medical professional.